 |
|
Evidence of Axonal Damage in the Early Stages of Multiple Sclerosis and Its Relevance to Disability
Nicola De Stefano, MD;
Sridar Narayanan, MSc;
Gordon S. Francis, MD;
Rozie Arnaoutelis, BSc;
Maria C. Tartaglia, BSc;
Jack P. Antel, MD;
Paul M. Matthews, MD;
Douglas L. Arnold, MD
Arch Neurol. 2001;58:65-70.
ABSTRACT
| |
Objective To assess axonal damage and its contribution to disability at different
stages of multiple sclerosis (MS).
Background Recent in vivo imaging and in situ pathologic studies have demonstrated
that substantial axonal damage accompanies the inflammatory lesions of MS.
However, the relation of axonal damage to the duration of MS and its contribution
to disability at different stages of the disease remain poorly defined.
Design We performed proton magnetic resonance spectroscopic imaging in 88 patients
with a wide range of clinical disability and disease duration to measure N-acetylaspartate (NAA, an index of axonal integrity) relative
to creatine (Cr) in a large central brain volume that included mostly normal-appearing
white matter on magnetic resonance imaging.
Results We observed that the NAA/Cr values were abnormally low in the early
stages of MS, even before significant disability (measured using the Expanded
Disability Status Scale [EDSS]) was evident clinically, and declined more
rapidly with respect to EDSS at lower than at higher EDSS scores (P<.001). The correlation of NAA/Cr values with EDSS score was significantly
(P<.03) stronger in patients with mild disability
(EDSS score <5, Spearman rank order correlation = –0.54, P< .001) than in patients with more severe disability (EDSS score  5,
Spearman rank order correlation = -0.1, P<.9).
When similar analyses were performed in patients with MS grouped for duration
of disease, the subgroup with early disease duration (<5 years) also showed
central brain NAA/Cr resonance intensity ratios significantly lower than healthy
controls (P<.001).
Conclusion Cerebral axonal damage begins and contributes to disability from the
earliest stages of the disease.
INTRODUCTION
THE IMPORTANCE of axonal injury in multiple sclerosis (MS) is being
increasingly appreciated.1, 2, 3, 4
Neuropathologic techniques have demonstrated that sparing of axons is only
relative in MS.5, 6 Pathologic
evidence of injured or transected axons is common in active MS lesions, and
chronic lesions show clear evidence of axonal injury.6, 7
Although there is increasing agreement that axonal loss is a major factor
contributing to disability in the later stages of MS,7, 8, 9
the relation of axonal damage to disability in the early stages of MS is less
clear.
Magnetic resonance spectroscopy (MRS) is particularly useful for the
study of axonal damage because it allows in vivo assessment of axonal dysfunction
or loss based on the signal intensity of N-acetylaspartate
(NAA), the main component of the peak dominating the normal proton spectrum,
which is localized almost exclusively in neurons and axons in mature human
brains.10, 11 Large decreases of
NAA not restricted to brain lesions were observed in the earliest proton MRS
studies of patients with well-established MS12
and have been confirmed in many subsequent reports (for review see Matthews
et al2). Spectroscopic studies also have demonstrated
a strong relation between changes in NAA and clinical disability both in acute
and chronic MS.13, 14, 15, 16, 17, 18
Interestingly, in these studies, it was NAA in normal-appearing white matter
that correlated best with disability.
Generalization from data reported so far, however, has been limited
by the small numbers of patients and the restricted disability range studied.
Therefore, we performed proton magnetic resonance spectroscopic imaging (MRSI)
examinations and concurrent clinical evaluations in a relatively large group
of patients with MS with a wide range of clinical disability and disease duration.
We then assessed the levels of NAA relative to creatine (Cr) in different
patient subgroups and examined the relevance of axonal injury to disability
in initial vs later stages of MS.
PATIENTS AND METHODS
STUDY POPULATION
Eighty-eight patients with clinically definite MS19
(48 women and 40 men; age range, 25-58 years) were chosen from the population
followed in the Montreal Neurological Hospital MS clinic. Patients were classified
according to clinical course as having either recurrent relapses (RR) with
complete or partial remission (n = 55; 32 women and 23 men) or secondary progressive
(SP) disease with progression in the absence of discrete relapses after earlier
relapsing-remitting disease (n = 33; 16 women and 17 men). Patients were entered
into the study only if they had been free from attacks in the previous month
to study a clinically relatively stable MS population and reduce the potential
confounding of reversible NAA and Cr changes occurring after acute relapses.13 Patients were stratified across a wide range of disability
(Expanded Disability Status Scale [EDSS] score20;
range, 0-9) and disease duration (range, 0.5-33 years). The whole patient
group could therefore be subdivided into smaller subgroups according to either
their EDSS score or their disease duration
(Table 1). The Montreal Neurological Hospital Ethics Committee approved
the study, and informed consent was obtained from all participating subjects.
|
|
|
|
N-Acetylaspartate-Creatine (NAA/Cr)
Values Relative to the Whole Group of Patients With Multiple Sclerosis (MS)
and Different Subgroups*
|
|
|
PROTON MRI AND MRSI OF BRAIN
Combined proton MRI and MRSI examinations of the brain were obtained
in a single session for each examination using a scanner operating at 1.5
T (Philips Gyroscan; Philips Medical Systems, Best, the Netherlands). A transverse
dual-echo, turbo spin-echo sequence (repetition time [TR], 2075 milliseconds;
echo time [TE] 1, 32 milliseconds; TE2, 90 milliseconds, 256 x 256 matrix,
1 signal average, 250-mm field of view), yielding proton density-weighted
and T2-weighted images with 50 contiguous 3-mm slices, was acquired parallel
to the line connecting the anterior and posterior commissures. These MRIs
were used to select an intracranial volume of interest (VOI) for spectroscopy
measuring approximately 100 mm anteroposteriorly by 20 mm craniocaudally by
90 mm left to right (Figure 1).
This was centered on the corpus callosum to include mostly white matter and
some mesial cortex of both hemispheres. Although the VOI used in this study
comprised only a limited portion of the whole brain, this included regions
where axonal projections converge after traversing large brain volumes. Thus,
NAA/Cr measures from this deep central brain region should reflect axonal
status in a fairly large volume of brain beyond that contained within the
spectroscopic VOI. Two-dimensional spectroscopic images were obtained using
a 90°, 180°, 180° pulse sequence (TR, 2000 milliseconds; TE, 272
milliseconds; 250-mm field of view; 32 x 32 phase-encoding steps; 1
signal average per step) as previously described.21
Magnetic field homogeneity was optimized to a line width of about 5 Hz over
the VOI using the proton signal from water. Water suppression was achieved
by placing frequency-selective excitation pulses at the beginning of the MRSI
sequence.22 Before the water-suppressed acquisition,
another MRSI was acquired without water suppression (TR, 850 milliseconds;
TE, 272 milliseconds; 250-mm field of view; and 16 x 16 phase-encoding
steps) to allow for B0 homogeneity correction.
|
|
|
|
Figure 1. Conventional T2-weighted magnetic
resonance imaging (MRI) scan of a patient with multiple sclerosis illustrating
the volume of interest (VOI, black box inside the MRI) used for spectroscopy
(left) and a set of proton spectra corresponding to the brain voxels (right).
Voxels at the edges of the VOI were not used because they can show artifactual
relative amplitudes. In the remaining voxels (white boxes inside the MRI), N-acetylaspartate (NAA) values were normalized to intravoxel creatine
(Cr) to correct for magnetic resonance inhomogeneities through the VOI. The
NAA/Cr values of the whole brain region were obtained by averaging NAA/Cr
values for all the voxels in the spectroscopic VOI for each subject.
|
|
|
PROTON MRSI DATA ANALYSIS
Postprocessing of the raw MRSI data included zero filling the non–water-suppressed
MRSI to obtain 32 x 32 profiles, followed by a mild gaussian k-space
filter and an inverse 2-dimensional Fourier transformation to both the water-suppressed
and unsuppressed MRSI. Artifacts present in the time domain water-suppressed
signal due to static magnetic field inhomogeneities and time-varying gradients
were corrected by dividing the water-suppressed MRSI signal by the non–water-suppressed
signal,23 a procedure that does not affect
relative signal intensities. The residual water signal was then fitted and
removed from the water-suppressed data using the Hankel singular-value decomposition
procedure.24 To enhance the resolution of the
spectral peaks, a lorentzian-to-gaussian transformation was applied before
Fourier transformation in the spectral domain. The nominal voxel size was
8 x 8 x 20 mm, giving a resolution of about 12 x 12 x
20 mm after k-space filtering. Metabolite resonance intensities of NAA and
Cr were determined automatically from peak areas relative to a spline-corrected
baseline. Results were expressed as the intravoxel ratio of NAA to Cr (a signal
arising mainly from both Cr and phosphocreatine). In vitro MRS analysis of
MS brains has demonstrated that Cr does not change in normal-appearing tissue.25 In the present study, we refer to Cr in the normal-appearing
white matter rather than in the lesions, because in the large central VOIs
examined, lesions accounted for only about 6% of the VOI in the whole group
of patients (range, 0.5%-25%; data not shown).
In our analysis, the relative NAA/Cr values of the whole brain region
were obtained by averaging the NAA/Cr values for all the voxels in the spectroscopic
VOI for each subject. Spectra at the edges of the VOI can be affected by chemical
shift artifacts associated with selective excitation and were deleted before
averaging (Figure 1). The average
NAA/Cr values of the MS patient group were compared with those of a group
of healthy adult controls (n = 17; age range, 24-56 years) using the nonparametric
Kruskal-Wallis test of variance. Central brain NAA/Cr values of the different
patient subgroups were compared using analysis of variance followed by pairwise
post hoc comparison using the Tukey honestly significant difference procedure
to account for multiple comparisons. Values of NAA/Cr of the whole MS patient
group and the different subgroups were then correlated with their corresponding
EDSS scores using the nonparametric Spearman rank order correlation (SROC).
Data were considered significant at the .05 level.
RESULTS
In the 88 patients with MS studied, the central brain NAA/Cr ratio was
significantly lower than in healthy controls (mean ± SD NAA/Cr ratio,
2.71 ± 0.31 and 3.20 ± 0.24, respectively; P<.001) (Table 1) and
was inversely correlated with disability (SROC = –0.55, P<.001). In this group of patients with MS, age did not correlate
with NAA/Cr levels (SROC = 0.04, P>.6), and there
were no differences in NAA/Cr values between men and women (mean ±
SD NAA/Cr ratio = 2.71 ± 0.33 for men with MS and 2.71 ± 0.29
for women with MS).
Analyses of subgroups based on clinical course, disability level, and
duration of disease were performed. Both the RR and SP subgroups exhibited
significantly lower NAA/Cr ratios than healthy controls (mean ± SD
NAA/Cr ratio = 2.77 ± 0.33 in patients with RR MS and 2.61 ±
0.25 in patients with SP MS; P<.001 for both groups).
Central brain NAA/Cr ratio was significantly lower in patients with SP MS
than in those with RR MS (P = .05). As in previous
studies,15, 16 the correlation
between decreasing NAA/Cr resonance intensity ratios and increasing EDSS scores
was stronger in patients with RR MS than in those with SP MS (SROC = -0.64
in RR MS patients, P<.001; SROC = -0.28
in SP MS patients, P<.1).
When a subgroup of MS patients with milder disability (EDSS score <5,
n = 50) was considered alone, central brain NAA/Cr resonance intensity ratios
were still significantly lower than healthy controls (mean ± SD NAA/Cr
ratio = 2.83 ± 0.28; P<.001). Further dividing
this patient subgroup into smaller EDSS groups revealed that decreases in
central brain NAA/Cr ratios were significant in patients with MS in the earliest
stages of the disease (Table 1).
Changes in NAA/Cr ratios as a function of EDSS were greater for patients with
mild disease than for the more severely affected patients. For example, the
mean decrease in NAA/Cr ratio between the patient subgroup with EDSS scores
of 0 to 1 and the subgroup with EDSS scores of 4 to 5 was about 15% (P = .001), whereas the decrease was only 5% between the
patient subgroup with EDSS scores of 4 to 5 and the subgroup with EDSS scores
of 8 to 9 (P = .1) (Figure 2). The correlation between NAA/Cr ratio and EDSS score was
significantly (P<.03) stronger in patients with
mild disability (EDSS score <5, SROC = –0.54, P< .001) than in the more disabled group (EDSS score 5, n =
38, SROC = -0.1, P = .9) (Figure 3).
|
|
|
|
Figure 2. Mean N-acetylaspartate–creatine
(NAA/Cr) ratios for patients with multiple sclerosis grouped by Expanded Disability
Status Scale (EDSS) score. In the different patient subgroups, analysis of
variance followed by pairwise post hoc comparison (Tukey honestly significant
difference procedure) showed that changes in NAA/Cr ratio with respect to
EDSS score are greater for patients with lower EDSS scores than for more disabled
patients (see the "Results" section). Shaded area indicates mean ±
SD of healthy controls.
|
|
|
|
|
|
|
Figure 3. Data from 88 patients with multiple
sclerosis illustrating the nonlinear decrease of N-acetylaspartate–creatine
(NAA/Cr) ratio with respect to Expanded Disability Status Scale (EDSS) score.
A significant relation can be seen in the group of patients with milder disability
(EDSS score <5, Spearman rank order correlation = –0.54, P<.001) but cannot be seen in the more disabled group (EDSS score 5,
Spearman rank order coefficient = -0.1, P= .9).
|
|
|
When similar analyses were performed in patients with MS grouped for
duration of disease, the subgroup with short disease duration (<5 years,
n = 21) also showed central brain NAA/Cr resonance intensity ratios (2.73
± 0.35) significantly lower than healthy controls (P<.001) and a close correlation between cerebral NAA/Cr ratio and
EDSS score (SROC = –0.70, P<.001) was found
(Figure 4). A significant correlation
was not found in patients with more long-standing disease.
|
|
|
|
Figure 4. Data from patients with multiple
sclerosis (MS) with disease duration of less than 5 years illustrating the
following: (A) the significant decrease in N-acetylaspartate–creatine
(NAA/Cr) ratio relative to the healthy control group (P<.001)
and (B) a very strong correlation between NAA/Cr ratio and Expanded Disability
Status Scale (EDSS) score (Spearman rank order correlation = –0.70, P<.001).
|
|
|
COMMENT
EARLY AXONAL DAMAGE IN MS
By assessing central brain NAA in a relatively large, clinically stable
MS population with a wide range of disability and disease duration, we showed
that diffuse cerebral axonal damage (1) begins in the early stages of MS,
(2) develops more rapidly in the earlier clinical stages of the disease, and
(3) correlates more strongly with disability in patients with mild disease
than in patients with more severe disease.
Our results emphasize that significant axonal pathology is not confined
to lesions and must occur early in the evolution of MS, ie, axonal injury
and loss is not restricted to the end stages of the disease. Even complete
clinical recovery from acute attacks in early MS does not mean that axonal
damage has not occurred. In the initial stages of MS, in addition to functional
recovery due to reversal of axonal conduction block associated with inflammation
and release of soluble factors,26 functional
impairment due to axonal damage and dysfunction may be compensated for by
mechanisms such as sodium channel redistribution27, 28
and brain plasticity.29, 30 In
fact, the presence of early axonal damage in MS has been suggested in recent
histological studies that showed that (1) axon degeneration can accompany
acute demyelination,31 (2) milder axonal changes
can occur before inflammation,32 and (3) axon
degeneration can be evident in MS lesions of individuals with no history of
neurologic symptoms.33, 34 These
in vitro observations lend support to our in vivo findings in suggesting that
axonal damage does accumulate and is relevant to disability from the early
stages of MS.
An interesting finding reported herein is that the decreases in NAA/Cr
ratio were faster with respect to EDSS score in earlier stages of MS than
in later stages. This should not be interpreted as evidence that axonal damage
contributes less to disability later in the course of MS. In fact, with the
progression of the disease, other mechanisms of axonal damage may become important
and be more sensitively assessed by other magnetic resonance measures (ie,
loss of brain and spinal cord parenchymal volume35).36, 37, 38 The loss of spinal
cord volume, for example, appears to be more evident in patients with SP MS
than in those with the relapsing form of the disease.37
Recent studies also have suggested that brain atrophy, although detectable
in patients with RR MS,39 is more prominent
in the progressive phase of MS. In addition, marked brain volume changes in
the later stages of MS might affect, to some extent, the sensitivity of NAA
measurements. Thus, the presence of more pronounced brain atrophy and spinal
cord pathology in late disease stages may explain, at least in part, the weaker
relation between NAA/Cr ratio and EDSS score found in our study of patients
with MS and severe disability.
NAA/Cr RATIO AS A MARKER OF AXONAL DAMAGE
We believe that NAA is a reliable marker of axonal integrity in the
adult brain. Antibodies directed against NAA or N-acetylaspartylglutamate
stain neurons strongly without staining glial cells.11, 40
The fact that O2A progenitor cells in culture express NAA41
has raised some concerns about the specificity of NAA changes in vivo. However,
O2A progenitor cells have been characterized only in culture. Related A2B5-positive
cells are believed to occur in vivo but do not appear to be abundant enough
to be able to contribute substantially to the total amount of NAA measured.42 A recent report43
has demonstrated that NAA can be detected in cultured, rat-derived O2A progenitor
cells and mature oligodendrocytes derived from them. However, it is not clear
that these in vitro conditions are relevant to the situation in vivo. There
is a need to reconcile the antibody data with these high-performance liquid
chromatography and nuclear magnetic resonance–based analyses. Regarding
the results presented herein, oligodendrocyte density appears not to be reduced
in normal-appearing white matter, which constitutes the majority of the tissue
in our spectroscopic VOI. Thus, the potential for NAA expression in oligodendrocytes
confounding our results appears to be minimal.44
Proton MRSI results are expressed in this study as NAA/Cr ratios. The
resonance intensity of intravoxel Cr has been widely used as internal standard
in MRS studies in vivo, since it is relatively equally present in all brain
cells and tends to be stable in chronic (ie, nonacute13)
pathologic conditions. Changes in apparent brain Cr concentrations have been
reported in chronic MS in recent MRS studies that attempted absolute quantitation.
However, all current quantitative approaches have important limitations when
applied to clinical studies and, in patients with MS, have shown discrepant
results, reporting in turn increases, decreases, and absence of Cr changes
in MRI lesions and in the normal-appearing white matter.17, 45, 46, 47, 48, 49, 50
We believe that the most reliable data come from a study using high-resolution
in vitro proton nuclear magnetic resonance spectroscopy (which does not have
the same limitations as in vivo quantitation) on postmortem MS tissue.25 This study showed that Cr was decreased in MS plaques
and that Cr levels were unchanged in the normal-appearing brain. In the present
study, lesions occupied, on average, about 6% of the brain VOI used for spectroscopy
(see the "Patients and Methods" section), suggesting that significant changes
in Cr resonance intensities are unlikely. Consistent with this, ratios of
choline to Cr resonance intensities in the group of patients with MS did not
differ from controls (data not shown).
CONCLUSIONS
Central brain NAA/Cr ratios reveal that axonal injury begins in the
early stages of MS. The strong correlation between NAA/Cr ratio and EDSS score
in patients with low disability and disease duration adds to accumulating
evidence that axonal damage is a primary determinant of disability from the
early stages of the disease. To better understand the contribution of axonal
loss to disability through the full course of the disease, the use of new
measures51 and the integration of multiple
magnetic resonance modalities (ie, brain NAA, cerebral and spinal cord volumes)
will be necessary. The close relation between axonal pathology and clinical
disability in the early stages of the disease argues for the early treatment
of MS with agents directed not only against inflammation but also toward axonal
protection.3, 52, 53
AUTHOR INFORMATION
Accepted for publication June 13, 2000.
This study was supported by grants from the Multiple Sclerosis Society
of Canada and the Medical Research Council of Canada and a pilot grant from
the National Multiple Sclerosis Society. Dr De Stefano was supported in part
by a grant from the Progetto Sclerosi Multipla, Istituto Superiore di Sanita',
Rome, Italy. Dr Matthews acknowledges support from the Medical Research Council
and the Multiple Sclerosis Society of Great Britain and Northern Ireland.
From the Department of Neurology and Neurosurgery, Montreal Neurological
Institute and Hospital, Montreal, Quebec (Drs De Stefano, Francis, Antel,
Matthews, and Arnold; Mr Narayanan; and Mss Arnaoutelis and Tartaglia); Institute
of Neurological Sciences and NMR Centre, University of Siena, Siena, Italy
(Dr De Stefano); and Centre for Functional Magnetic Resonance Imaging of the
Brain, Department of Clinical Neurology, University of Oxford, Oxford, England
(Dr Matthews).
Corresponding author: Nicola De Stefano, MD, Institute of Neurological
Science, Viale Bracci 2, 53100, Siena, Italy (e-mail: destefano{at}unisi.it).
REFERENCES
| |
1. McDonald WI. Rachelle Fishman-Matthew Moore Lecture: the pathological and clinical
dynamics of multiple sclerosis [review]. J Neuropathol Exp Neurol. 1994;53:338-343.
ISI
| PUBMED
2. Matthews PM, De Stefano N, Narayanan S, et al. Putting magnetic resonance spectroscopy studies in context: axonal
damage and disability in multiple sclerosis. Semin Neurol. 1998;18:327-336.
ISI
| PUBMED
3. Trapp BD, Ransohoff R, Rudick R. Axonal pathology in multiple sclerosis: relationship to neurological
disability. Curr Opin Neurol. 1999;12:295-302.
FULL TEXT
|
ISI
| PUBMED
4. Waxman SG. Multiple sclerosis as a neuronal disease [editorial; comment]. Arch Neurol. 2000;57:22-24.
FREE FULL TEXT
5. Ferguson B, Matyszak MK, Esiri MM, Perry VH. Axonal damage in acute multiple sclerosis lesions. Brain. 1997;120:393-399.
FREE FULL TEXT
6. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med. 1998;338:278-285.
FREE FULL TEXT
7. Silber E, Sharief MK. Axonal degeneration in the pathogenesis of multiple sclerosis. J Neurol Sci. 1999;170:11-18.
FULL TEXT
|
ISI
| PUBMED
8. Barnes D, Munro PMG, Youl BD, Prineas JW, McDonald WI. The longstanding MS lesion: a quantitative MRI and electron microscopic
study. Brain. 1991;114:1271-1280.
FREE FULL TEXT
9. Scolding N, Franklin R. Axon loss in multiple sclerosis. Lancet. 1998;352:340-341.
FULL TEXT
|
ISI
| PUBMED
10. Birken DL, Oldendorf WH. N-acetyl-L-aspartic acid: a literature review
of a compound prominent in 1H-NMR spectroscopic studies of brain. Neurosci Biobehav Rev. 1989;13:23-31.
FULL TEXT
|
ISI
| PUBMED
11. Simmons ML, Frondoza CG, Coyle JT. Immunocytochemical localization of N-acetyl-aspartate
with monoclonal antibodies. Neuroscience. 1991;45:37-45.
FULL TEXT
|
ISI
| PUBMED
12. Arnold DL, Matthews PM, Francis G, Antel J. Proton magnetic resonance spectroscopy of human brain in vivo in the
evaluation of multiple sclerosis: assessment of the load of disease. Magn Reson Med. 1990;14:154-159.
ISI
| PUBMED
13. De Stefano N, Matthews PM, Antel JP, Preul M, Francis G, Arnold DL. Chemical pathology of acute demyelinating lesions and its correlation
with disability. Ann Neurol. 1995;38:901-909.
FULL TEXT
|
ISI
| PUBMED
14. Davie CA, Barker GJ, Webb S, et al. Persistent functional deficit in multiple sclerosis and autosomal dominant
cerebellar ataxia is associated with axon loss. Brain. 1995;118:1583-1592.
FREE FULL TEXT
15. Fu L, Matthews PM, De Stefano N, et al. Imaging axonal damage of normal-appearing white matter in multiple
sclerosis. Brain. 1998;121:103-113.
FREE FULL TEXT
16. De Stefano N, Matthews PM, Fu L, et al. Axonal damage correlates with disability in patients with relapsing-remitting
multiple sclerosis: results of a longitudinal magnetic resonance spectroscopy
study. Brain. 1998;121:1469-1477.
FREE FULL TEXT
17. Davie CA, Silver NC, Barker GJ, et al. Does the extent of axonal loss and demyelination from chronic lesions
in multiple sclerosis correlate with the clinical subgroup? J Neurol Neurosurg Psychiatry. 1999;67:710-715.
FREE FULL TEXT
18. Lee MA, Blamire AM, Pendlebury S, et al. Axonal injury or loss in the internal capsule and motor impairment
in multiple sclerosis. Arch Neurol. 2000;57:65-70.
FREE FULL TEXT
19. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research
protocols. Ann Neurol. 1983;13:227-231.
FULL TEXT
|
ISI
| PUBMED
20. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an Expanded Disability
Status Scale (EDSS). Neurology. 1983;33:1444-1452.
FREE FULL TEXT
21. De Stefano N, Matthews PM, Arnold DL. Reversible decreases in N-acetylaspartate
after acute brain injury. Magn Reson Med. 1995;34:721-727.
ISI
| PUBMED
22. Haase A, Frahm J, Hanicke W, Matthaei D. 1H NMR chemical shift selective (CHESS) imaging. Phys Med Biol. 1985;30:341-344.
FULL TEXT
|
ISI
| PUBMED
23. den Hollander JA, Oosterwaal B, van Vroonhoven H, Luyten PR. Elimination of magnetic field distortions in 1H NMR spectroscopic
imaging [abstract]. Proc Soc Magn Reson Med. 1991;1:472.
24. de Beer R, Van den Boogaart A, van Ormondt D, et al. Application of time-domain fitting in the quantification of in vivo 1H spectroscopic imaging data sets. NMR Biomed. 1992;5:171-178.
ISI
| PUBMED
25. Davies SE, Newcombe J, Williams SR, McDonald WI, Clark JB. High resolution proton NMR spectroscopy of multiple sclerosis lesions. J Neurochem. 1995;64:742-748.
ISI
| PUBMED
26. Smith KJ, Kapoor R, Felts PA. Demyelination: the role of reactive oxygen and nitrogen species. Brain Pathol. 1999;9:69-92.
ISI
| PUBMED
27. Moll C, Mourre C, Lazdunski M, Ulrich J. Increase of sodium channels in demyelinated lesions of multiple sclerosis. Brain Res. 1991;556:311-316.
FULL TEXT
|
ISI
| PUBMED
28. Black JA, Felts P, Smith KJ, Kocsis JD, Waxman SG. Distribution of sodium channels in chronically demyelinated spinal
cord axons: immuno-ultrastructural localization and electrophysiological observations. Brain Res. 1991;544:59-70.
FULL TEXT
|
ISI
| PUBMED
29. Waxman SG. Molecular remodeling of neurons in multiple sclerosis: what we know,
and what we must ask about brain plasticity in demyelinating diseases. Adv Neurol. 1997;73:109-120.
ISI
| PUBMED
30. Reddy H, Narayanan S, Matthews PM, et al. Relating axonal injury to functional recovery in MS. Neurology. 2000;54:236-239.
FREE FULL TEXT
31. Silver NC, Barker RA, MacManus DG, et al. Proton magnetic resonance spectroscopy in a pathologically confirmed
acute demyelinating lesion [letter]. J Neurol. 1997;244:204-207.
FULL TEXT
|
ISI
| PUBMED
32. Zhu B, Moore GR, Zwimpfer TJ, et al. Axonal cytoskeleton changes in experimental optic neuritis. Brain Res. 1999;824:204-217.
FULL TEXT
|
ISI
| PUBMED
33. Mews I, Bergmann M, Bunkowski S, Gullotta F, Bruck W. Oligodendrocyte and axon pathology in clinically silent multiple sclerosis
lesions. Mult Scler. 1998;4:55-62.
FREE FULL TEXT
34. Trapp BD, Ransohoff RM, Fisher E, Rudick RA. Neurodegeneration in multiple sclerosis: relationship to neurological
disability. Neuroscientist. 1999;5:48-57.
FREE FULL TEXT
35. Filippi M, Colombo B, Rovaris M, Pereira C, Martinelli V, Comi G. A longitudinal magnetic resonance imaging study of the cervical cord
in multiple sclerosis. J Neuroimaging. 1997;7:78-80.
ISI
| PUBMED
36. Losseff NA, Miller DH. Measures of brain and spinal cord atrophy in multiple sclerosis. J Neurol Neurosurg Psychiatry. 1998;64(suppl 1):S102-S105.
37. Stevenson VL, Leary SM, Losseff NA, et al. Spinal cord atrophy and disability in MS: a longitudinal study. Neurology. 1998;51:234-238.
FREE FULL TEXT
38. Nijeholt GJ, van Walderveen MA, Castelijns JA, et al. Brain and spinal cord abnormalities in multiple sclerosis: correlation
between MRI parameters, clinical subtypes and symptoms. Brain. 1998;121:687-697.
FREE FULL TEXT
39. Simon JH, Jacobs LD, Campion MK, et al. A longitudinal study of brain atrophy in relapsing multiple sclerosis:
the Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology. 1999;53:139-148.
FREE FULL TEXT
40. Moffett JR, Namboodiri MAA, Cangro CB, Neale JH. Immunohistochemical localization of N-acetylaspartate
in rat brain. Neuroreport. 1991;2:131-134.
ISI
| PUBMED
41. Urenjak J, Williams SR, Gadian DG, Noble M. Proton nuclear magnetic resonance spectroscopy unambiguously identifies
different neural cell types. J Neurosci. 1993;13:981-989.
ABSTRACT
42. Scolding N, Franklin R, Stevens S, Heldin CH, Compston A, Newcombe J. Oligodendrocyte progenitors are present in the normal adult human CNS
and in the lesions of multiple sclerosis. Brain. 1998;121:2221-2228.
FREE FULL TEXT
43. Bhakoo KK, Pearce D. In vitro expression of N-acetyl aspartate
by oligodendrocytes: implications for proton magnetic resonance spectroscopy
signal in vivo. J Neurochem. 2000;74:254-262.
FULL TEXT
|
ISI
| PUBMED
44. Wolswijk G. Chronic stage multiple sclerosis lesions contain a relatively quiescent
population of oligodendrocyte precursor cells. J Neurosci. 1998;18:601-609.
FREE FULL TEXT
45. Husted CA, Goodin DS, Hugg JW, et al. Biochemical alterations in multiple sclerosis lesions and normal-appearing
white matter detected by in vivo 31P and 1H spectroscopic
imaging. Ann Neurol. 1994;36:157-165.
FULL TEXT
|
ISI
| PUBMED
46. Pan JW, Hetherington HP, Vaughan JT, Mitchell G, Pohost GM, Whitaker JN. Evaluation of multiple sclerosis by 1H spectroscopic imaging
at 4.1 T. Magn Reson Med. 1996;36:72-77.
ISI
| PUBMED
47. Davie CA, Barker GJ, Thompson AJ, Tofts PS, McDonald WI, Miller DH. 1H magnetic resonance spectroscopy of chronic cerebral white
matter lesions and normal appearing white matter in multiple sclerosis. J Neurol Neurosurg Psychiatry. 1997;63:736-742.
FREE FULL TEXT
48. Sarchielli P, Presciutti O, Pelliccioli GP, et al. Absolute quantification of brain metabolites by proton magnetic resonance
spectroscopy in normal-appearing white matter of multiple sclerosis patients. Brain. 1999;122:513-521.
FREE FULL TEXT
49. van Walderveen MA, Barkhof F, Pouwels PJ, van SR, Polman CH, Castelijns JA. Neuronal damage in T1-hypointense multiple sclerosis lesions demonstrated
in vivo using proton magnetic resonance spectroscopy. Ann Neurol. 1999;46:79-87.
FULL TEXT
|
ISI
| PUBMED
50. Narayana PA, Doyle TJ, Lai D, Wolinsky JS. Serial proton magnetic resonance spectroscopic imaging, contrast-enhanced
magnetic resonance imaging, and quantitative lesion volumetry in multiple
sclerosis. Ann Neurol. 1998;43:56-71.
FULL TEXT
|
ISI
| PUBMED
51. Gonen O, Catalaa I, Babb JS, et al. Total brain N-acetylaspartate: a new measure
of disease load in MS. Neurology. 2000;54:15-19.
FREE FULL TEXT
52. Compston A. Future options for therapies to limit damage and enhance recovery. Semin Neurol. 1998;18:405-414.
ISI
| PUBMED
53. Demerens C, Stankoff B, Zalc B, Lubetzki C. Eliprodil stimulates CNS myelination: new prospects for multiple sclerosis? Neurology. 1999;52:346-350.
FREE FULL TEXT
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLES
Archives of Neurology Reader's Choice: Continuing Medical Education
Arch Neurol. 2001;58(1):149-151.
FULL TEXT
A Real-Time Insight Into Disease Progression and the Role of Axonal Injury in Multiple Sclerosis
Carl Bjartmar, Grahame Kidd, and Richard M. Ransohoff
Arch Neurol. 2001;58(1):37-39.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Review: Treatment of early multiple sclerosis: the value of treatment initiation after a first clinical episode
Goodin and Bates
Mult Scler 2009;15:1175-1182.
ABSTRACT
In-vivo evidence for stable neuroaxonal damage in the brain of patients with benign multiple sclerosis
Benedetti et al.
Mult Scler 2009;15:789-794.
ABSTRACT
Progressive Multifocal Leukoencephalopathy and Relapsing-Remitting Multiple Sclerosis: A Comparative Study
Boster et al.
Arch Neurol 2009;66:593-599.
ABSTRACT
| FULL TEXT
Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis
Teunissen et al.
Neurology 2009;72:1322-1329.
ABSTRACT
| FULL TEXT
Axial Diffusivity Is the Primary Correlate of Axonal Injury in the Experimental Autoimmune Encephalomyelitis Spinal Cord: A Quantitative Pixelwise Analysis
Budde et al.
J. Neurosci. 2009;29:2805-2813.
ABSTRACT
| FULL TEXT
Structural and metabolic brain abnormalities in preclinical cerebral autosomal dominant arteriopathy with subcortical infarcts and leucoencephalopathy
Stromillo et al.
J. Neurol. Neurosurg. Psychiatry 2009;80:41-47.
ABSTRACT
| FULL TEXT
Canadian treatment optimization recommendations (TOR) as a predictor of disease breakthrough in patients with multiple sclerosis treated with interferon {beta}-1a: analysis of the PRISMS study
Freedman and Forrestal
Mult Scler 2008;14:1234-1241.
ABSTRACT
Protecting axons in multiple sclerosis
Wilkins and Scolding
Mult Scler 2008;14:1013-1025.
ABSTRACT
Magnetic resonance imaging metrics and their correlation with clinical outcomes in multiple sclerosis: a review of the literature and future perspectives
Bar-Zohar et al.
Mult Scler 2008;14:719-727.
ABSTRACT
Clinically benign multiple sclerosis despite large T2 lesion load: Can we explain this paradox?
Strasser-Fuchs et al.
Mult Scler 2008;14:205-211.
ABSTRACT
Guidelines for using proton MR spectroscopy in multicenter clinical MS studies
De Stefano et al.
Neurology 2007;69:1942-1952.
ABSTRACT
| FULL TEXT
Prominent brain axonal damage and functional reorganization in "pure" adrenomyeloneuropathy
Marino et al.
Neurology 2007;69:1261-1269.
ABSTRACT
| FULL TEXT
Axonal Damage But No Increased Glial Cell Activity in the Normal-Appearing White Matter of Patients with Clinically Isolated Syndromes Suggestive of Multiple Sclerosis Using High-Field Magnetic Resonance Spectroscopy
Wattjes et al.
Am. J. Neuroradiol. 2007;28:1517-1522.
ABSTRACT
| FULL TEXT
Determinants of Disability in Multiple Sclerosis at Various Disease Stages: A Multiparametric Magnetic Resonance Study
Pulizzi et al.
Arch Neurol 2007;64:1163-1168.
ABSTRACT
| FULL TEXT
Axonal loss is progressive and partly dissociated from lesion load in early multiple sclerosis
Pascual et al.
Neurology 2007;69:63-67.
ABSTRACT
| FULL TEXT
Experimental models of neuroprotection relevant to multiple sclerosis
Yong et al.
Neurology 2007;68:S32-S37.
ABSTRACT
| FULL TEXT
Acute metabolic brain changes following traumatic brain injury and their relevance to clinical severity and outcome
Marino et al.
J. Neurol. Neurosurg. Psychiatry 2007;78:501-507.
ABSTRACT
| FULL TEXT
Reproducibility of Three Whole-Brain N-Acetylaspartate Decline Cohorts in Relapsing-Remitting Multiple Sclerosis
Gonen et al.
Am. J. Neuroradiol. 2007;28:267-271.
ABSTRACT
| FULL TEXT
Neuronal Damage in Brain Inflammation
Aktas et al.
Arch Neurol 2007;64:185-189.
ABSTRACT
| FULL TEXT
Clinically isolated syndromes: A new oligoclonal band test accurately predicts conversion to MS
Masjuan et al.
Neurology 2006;66:576-578.
ABSTRACT
| FULL TEXT
Insights Into the Molecular Pathogenesis of Progression in Multiple Sclerosis: Potential Implications for Future Therapies
Imitola et al.
Arch Neurol 2006;63:25-33.
ABSTRACT
| FULL TEXT
1H-MRS quantification of tNA and tCr in patients with multiple sclerosis: a meta-analytic review
Caramanos et al.
Brain 2005;128:2483-2506.
ABSTRACT
| FULL TEXT
Motor neuron pathology in experimental autoimmune encephalomyelitis: studies in THY1-YFP transgenic mice
Bannerman et al.
Brain 2005;128:1877-1886.
ABSTRACT
| FULL TEXT
Brain atrophy and lesion load in a large population of patients with multiple sclerosis
Tedeschi et al.
Neurology 2005;65:280-285.
ABSTRACT
| FULL TEXT
Trigeminal neuralgia in a patient with multiple sclerosis and chronic inflammatory demyelinating polyneuropathy
SARLANI et al.
Journal of the American Dental Association 2005;136:469-476.
ABSTRACT
| FULL TEXT
Interferon Beta Promotes Nerve Growth Factor Secretion Early in the Course of Multiple Sclerosis
Biernacki et al.
Arch Neurol 2005;62:563-568.
ABSTRACT
| FULL TEXT
Regional Brain Atrophy Evolves Differently in Patients with Multiple Sclerosis According to Clinical Phenotype
Pagani et al.
Am. J. Neuroradiol. 2005;26:341-346.
ABSTRACT
| FULL TEXT
Spectroscopic evidence of cerebral axonopathy in patients with "pure" adrenomyeloneuropathy
Dubey et al.
Neurology 2005;64:304-310.
ABSTRACT
| FULL TEXT
The unique impact of changes in normal appearing brain tissue on cognitive dysfunction in secondary progressive multiple sclerosis patients
Cox et al.
Mult Scler 2004;10:626-629.
ABSTRACT
Corpus Callosum Axonal Injury in Multiple Sclerosis Measured by Proton Magnetic Resonance Spectroscopic Imaging
Oh et al.
Arch Neurol 2004;61:1081-1086.
ABSTRACT
| FULL TEXT
The pathogenesis of multiple sclerosis: is it really a primary inflammatory process?
Maggs and Palace
Mult Scler 2004;10:326-329.
ABSTRACT
Elevated white matter myo-inositol in clinically isolated syndromes suggestive of multiple sclerosis
Fernando et al.
Brain 2004;127:1361-1369.
ABSTRACT
| FULL TEXT
Multicentre proton magnetic resonance spectroscopy imaging of primary progressive multiple sclerosis
Narayana et al.
Mult Scler 2004;10:S73-S78.
ABSTRACT
Neural Stem/Progenitor Cells Express Costimulatory Molecules That Are Differentially Regulated by Inflammatory and Apoptotic Stimuli
Imitola et al.
Am. J. Pathol. 2004;164:1615-1625.
ABSTRACT
| FULL TEXT
Multicentre proton magnetic resonance spectroscopy imaging of primary progressive multiple sclerosis
Narayana et al.
Mult Scler 2004;10:S73-S78.
ABSTRACT
The Relationship Between Diffuse Axonal Damage and Fatigue in Multiple Sclerosis
Tartaglia et al.
Arch Neurol 2004;61:201-207.
ABSTRACT
| FULL TEXT
MRI/MRS of corpus callosum in patients with clinically isolated syndrome suggestive of multiple sclerosis
Ranjeva et al.
Mult Scler 2003;9:554-565.
ABSTRACT
Cannabinoids inhibit neurodegeneration in models of multiple sclerosis
Pryce et al.
Brain 2003;126:2191-2202.
ABSTRACT
| FULL TEXT
Genetic programs and responses of neural stem/progenitor cells during demyelination: potential insights into repair mechanisms in multiple sclerosis
Imitola et al.
Physiol. Genomics 2003;14:171-197.
ABSTRACT
| FULL TEXT
Cognitive performance and MR markers of cerebral injury in cognitively impaired MS patients
Christodoulou et al.
Neurology 2003;60:1793-1798.
ABSTRACT
| FULL TEXT
MRI and proton MRSI in women heterozygous for X-linked adrenoleukodystrophy
Fatemi et al.
Neurology 2003;60:1301-1307.
ABSTRACT
| FULL TEXT
Therapeutic vaccine for acute and chronic motor neuron diseases: Implications for amyotrophic lateral sclerosis
Angelov et al.
Proc. Natl. Acad. Sci. USA 2003;100:4790-4795.
ABSTRACT
| FULL TEXT
Evidence of early cortical atrophy in MS: Relevance to white matter changes and disability
De Stefano et al.
Neurology 2003;60:1157-1162.
ABSTRACT
| FULL TEXT
Coefficient Dav Is More Sensitive Than Fractional Anisotropy in Monitoring Progression of Irreversible Tissue Damage in Focal Nonactive Multiple Sclerosis Lesions
Castriota-Scanderbeg et al.
Am. J. Neuroradiol. 2003;24:663-670.
ABSTRACT
| FULL TEXT
Cognitive impairment in probable multiple sclerosis
Achiron and Barak
J. Neurol. Neurosurg. Psychiatry 2003;74:443-446.
ABSTRACT
| FULL TEXT
Magnetic resonance-based techniques for the study and management of multiple sclerosis
Rovaris et al.
Br Med Bull 2003;65:133-144.
ABSTRACT
| FULL TEXT
Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis
Filippi et al.
Brain 2003;126:433-437.
ABSTRACT
| FULL TEXT
Brain Metabolite Profiles of T1-Hypointense Lesions in Relapsing-Remitting Multiple Sclerosis
Li et al.
Am. J. Neuroradiol. 2003;24:68-74.
ABSTRACT
| FULL TEXT
Functional brain reorganization for hand movement in patients with multiple sclerosis: defining distinct effects of injury and disability
Reddy et al.
Brain 2002;125:2646-2657.
ABSTRACT
| FULL TEXT
Randomized, comparative study of interferon {beta}-1a treatment regimens in MS: The EVIDENCE Trial
Panitch et al.
Neurology 2002;59:1496-1506.
ABSTRACT
| FULL TEXT
Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time
Kuhlmann et al.
Brain 2002;125:2202-2212.
ABSTRACT
| FULL TEXT
Brain metabolite changes in cortical grey and normal-appearing white matter in clinically early relapsing-remitting multiple sclerosis
Chard et al.
Brain 2002;125:2342-2352.
ABSTRACT
| FULL TEXT
Diffuse Axonal and Tissue Injury in Patients With Multiple Sclerosis With Low Cerebral Lesion Load and No Disability
De Stefano et al.
Arch Neurol 2002;59:1565-1571.
ABSTRACT
| FULL TEXT
Relapsing-remitting Multiple Sclerosis and Whole-Brain N-Acetylaspartate Measurement: Evidence for Different Clinical Cohorts—Initial Observations
Gonen et al.
Radiology 2002;225:261-268.
ABSTRACT
| FULL TEXT
Key issues in the diagnosis and treatment of multiple sclerosis: An overview
O'Connor
Neurology 2002;59:S1-33.
FULL TEXT
Quantitative 1H MRS imaging 14 years after presenting with a clinically isolated syndrome suggestive of multiple sclerosis
Kapeller et al.
Mult Scler 2002;8:207-210.
ABSTRACT
Regional N-Acetylaspartate Reduction in the Hippocampus Detected With Fast Proton Magnetic Resonance Spectroscopic Imaging in Patients With Alzheimer Disease
Block et al.
Arch Neurol 2002;59:828-834.
ABSTRACT
| FULL TEXT
MRI techniques to monitor MS evolution: The present and the future
Filippi and Grossman
Neurology 2002;58:1147-1153.
ABSTRACT
| FULL TEXT
Whole-Brain N-Acetylaspartate Concentration: Correlation with T2-Weighted Lesion Volume and Expanded Disability Status Scale Score in Cases of Relapsing-Remitting Multiple Sclerosis
Bonneville et al.
Am. J. Neuroradiol. 2002;23:371-375.
ABSTRACT
| FULL TEXT
Axonal damage is a late component of vacuolar myelopathy
Rottnek et al.
Neurology 2002;58:479-481.
ABSTRACT
| FULL TEXT
Medical Hypothesis: Why Secondary Progressive Multiple Sclerosis Is a Relentlessly Progressive Illness
Herndon
Arch Neurol 2002;59:301-304.
ABSTRACT
| FULL TEXT
Correlates of MS disability assessed in vivo using aggregates of MR quantities
Mainero et al.
Neurology 2001;56:1331-1334.
ABSTRACT
| FULL TEXT
A Real-Time Insight Into Disease Progression and the Role of Axonal Injury in Multiple Sclerosis
Bjartmar et al.
Arch Neurol 2001;58:37-39.
FULL TEXT
|
